Danish pharmaceutical giant Novo Nordisk announced on November 10th that it plans to invest over 42 billion Danish kroner (approximately $6 billion) starting this year to expand its existing production facility in Karenburg, Denmark, for the current and future severe chronic disease product portfolio.
Novo Nordisk stated that investment will create more production capacity for the entire global value chain, from API production to packaging, with "the vast majority of investment going to API production capacity". The statement states that this investment includes the GLP-1 product, which will enhance Novo Nordisk's ability to meet future market demand.
Novo Nordisk stated that the construction project will be gradually completed from the end of 2025 to 2029, and upon completion, it will create over 8000 new jobs.